Advertisement


Related Videos

Matthew Seymour, MD: A Clinical Trialist’s Perspective

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Peter Clark, MA, MD, FRCP: A Payer Perspective

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Advertisement

Advertisement




Advertisement